脾窦岸细胞血管肉瘤1例并文献复习  

Littoral cell angiosarcoma:a case report and literature review

作　　者：张鹏[1] 李桂香[1] Zhang Peng;Li Guixiang(Cancer Center of Lanzhou University Second Hospital,Lanzhou 730030,China)

机构地区：[1]兰州大学第二医院肿瘤中心,兰州730030

出　　处：《中华转移性肿瘤杂志》2024年第5期492-495,共4页Chinese Journal of Metastatic Cancer

摘　　要：通过回顾1例脾窦岸细胞血管肉瘤(LCAS)的中年女性临床资料并进行文献复习,讨论此类肿瘤的临床表现、影像学表现、病理诊断及治疗。该患者以"脾占位性病变"收住院,术后病理检查提示LCAS。2022年3月起先后予以紫杉醇酯质体、表柔比星联合其他药物化疗7周期,2023年4月发现继发肝转移予以安罗替尼靶向治疗联合化疗4周期,患者于2023年8月离世。LCAS为罕见的恶性肿瘤,治疗上可参考血管肉瘤,手术治疗对于患者生存获益及诊断均有益处,术后可应用化疗、放疗等手段辅助治疗,以紫杉醇类或蒽环类药物为基础是LCAS的一线化疗方案。By studying retrospectively the clinical data of a middle-aged female case of littoral cell angiosarcoma(LCAS)and reviewing literature,the clinical manifestations,imaging manifestations,pathological diagnosis and treatment of this type of tumor were discussed.The patient was admitted with"splenic space-occupying lesion",and the postoperative pathological examination showed LCAS.From March 2022,she was given 7 cycles of chemotherapy with paclitaxel liposome and epirubicin combined with other drugs.In April 2023,secondary liver metastasis was discovered.The patient was given anlotinib targeted therapy combined with chemotherapy for 4 cycles and died in August 2023.LCAS is a rare malignant tumor and reference can be made to angiosarcoma for treatment.Surgical treatment is beneficial to both patient survival and diagnosis.Chemotherapy,radiotherapy and other means can be used as adjuvant treatment after surgery.Taxanes or anthracyclines are the first-line chemotherapy regimen for LCAS.

关 键 词：脾窦岸细胞血管肉瘤 鉴别诊断 治疗方法 

分 类 号：R733.2[医药卫生—肿瘤]